Is Bio-Techne (TECH) overvalued or fairly valued?

MarketChacha shows Bio-Techne's valuation in context — a trailing P/E of about 77.0, a forward P/E of about 31.4, a price-to-book of about 5.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Bio-Techne's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.60×) from reported figures — education, not a rating.

What is Bio-Techne's revenue?

Bio-Techne reported revenue of $1.2B for FY2025, with net profit of $73.4M, per official filings.

What is the share price of Bio-Techne (TECH)?

Bio-Techne last traded at $72.42 (-0.0% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Bio-Techne

TECH · NASDAQ · Healthcare · United States

Snapshot

TickerTECH

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees3,000

HeadquartersMinneapolis, United States

Websitewww.bio-techne.com

Filings tracked11

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

816 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.8.94%
FMR, LLC8.16%
Vanguard Capital Management LLC6.52%
Goldman Sachs Group Inc4.68%
HBK Investments L P4.35%
Vanguard Portfolio Management LLC4.15%
Morgan Stanley4.07%
State Street Corporation3.81%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 19.1 points over the period — profitability is trending down.

Cash conversion1.60×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend25.1% → 6.0%

Margin has compressed by about 19.1 points over the period — profitability is trending down.

Growth qualityrev 4% · PAT -49%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $308.0M · EPS 0.48

Est. earnings growth +4.7%

Next fiscal year

Rev $1.4B · EPS 1.70

Est. earnings growth +14.3%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.2B

Net margin

6.0%

Revenue CAGR (2y)

+3.6%

Profit CAGR (2y)

-49.3%

EPS (FY2025)

0.46

Net profit (FY2025)

$73.4M

Ask MarketChacha about TECH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.2B	$73.4M	0.46	6.0%	—
FY2024	$1.2B	$168.1M	1.05	14.5%	8.1%
FY2023	$1.1B	$285.3M	1.76	25.1%	14.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$311.4M	$51.0M	0.32	16.4%
2025Q4	$295.9M	$38.0M	0.24	12.8%
2025Q3	$286.6M	$38.2M	0.24	13.3%
2025Q1	$316.2M	$22.6M	0.14	7.1%
2024Q4	$297.0M	$34.9M	0.22	11.7%
2024Q3	$289.5M	$33.6M	0.21	11.6%
2024Q1	$303.4M	$49.1M	0.31	16.2%
2023Q4	$272.6M	$27.5M	0.17	10.1%
2023Q3	$276.9M	$51.0M	0.31	18.4%
2023Q1	$294.1M	$70.2M	0.43	23.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Material agreement, Executive/director change, Exhibits
SEC6/26/2026material
8-K — Reg FD disclosure, Exhibits
SEC6/25/2026material
8-K — Results of operations, Other events, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Executive/director change, Other events, Exhibits
SEC2/11/2026material
8-K — Results of operations, Other events, Exhibits
SEC2/4/2026material
10-Q filing
SEC2/4/2026

2025

8-K — Results of operations, Shareholder vote results, Other events, Exhibits
SEC11/5/2025material
10-Q filing
SEC11/5/2025
10-K filing
SEC8/22/2025
8-K — Results of operations, Other events, Exhibits
SEC8/6/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.